Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (INM)
NASDAQ:INM
INM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.72 - $15.69
Previous CloseN/A
Volume49.03K
Average Volume (3M)3.86M
Market Cap
$5.29M
Enterprise Value-$4.26B
Total Cash (Recent Filing)$4.72B
Total Debt (Recent Filing)$419.35M
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Sep 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding2,002,186
10 Day Avg. Volume213,544
30 Day Avg. Volume3,856,398
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-805.43
Enterprise Value/Revenue-160.99
Enterprise Value/Gross Profit-1.92K
Enterprise Value/Ebitda109.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
InMed Pharmaceuticals News
PremiumCompany Announcements
InMed Pharmaceuticals to Present Promising INM-901 Data at AAIC 2025PremiumCompany Announcements
InMed Pharmaceuticals Secures $5M in Private Placement
Options Prices
Currently, No data available
---
Ownership Overview
19.32% Insiders
<0.01% Other Institutional Investors
80.68% Public Companies and
Individual Investors
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $1.72 and its highest was $15.69 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $5.29M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 19, 2025 which is in 53 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 12, 2025. The company reported -$1.94 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.94.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 2,002,186 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$1.94 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.912%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
Titan Pharmaceuticals
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―